



July 1, 2024

**Dr. Reddy's Laboratories, Inc.**

**Notice Regarding the Discontinuation of the Ingenus Liquid Cyclophosphamide and NDC Change to Dr. Reddy's Laboratories Product and Impact on 340B Inventory Management/Accumulators**

Dr. Reddy's Laboratories, Inc. ("Dr. Reddy's") has asked the Office of Pharmacy Affairs ("OPA") to post this notice on OPA's public website to notify 340B covered entities that the national drug code ("NDC") numbers for Ingenus Liquid Cyclophosphamide will no longer be supplied to the US market and any current wholesaler inventory will be or is depleted. Dr. Reddy's will supply Liquid Cyclophosphamide going forward and the transition to NDCs are as follows:

<b>Product Description</b>	<b>Discontinued Ingenus NDC/Product</b>	<b>Dr Reddy's Laboratories NDCs</b>
Cyclophosphamide Injection 500mg/2.5mL	50742-0519-02	75907-0191-02
Cyclophosphamide Injection 1gm/5mL	50742-0520-05	75907-0190-07
Cyclophosphamide Injection 2gm/10mL	50742-0521-10	75907-0189-35

The wholesalers will continue to sell the remaining inventory of Ingenus product until exhausted, at any time beginning July 1<sup>st</sup>, you may switch to Dr. Reddy's NDCs and be assured that there is no difference between the to-be-discontinued Ingenus (NDA holder) product and the Dr. Reddy's product that is supplied by Ingenus.

The Dr. Reddy's NDC does not signify any change in product form, strength, or composition. Because the Dr. Reddy's NDCs represent the same product with the same 340B pricing as the old NDCs, Dr. Reddy's will permit eligible 340B covered entities using a compliant 340B inventory replenishment model to count accumulations of each old NDC towards replenishment of equal quantities of each corresponding Dr. Reddy's NDC.

Any questions regarding this notice can be sent to Dr. Reddy's at [customerservice@drreddys.com](mailto:customerservice@drreddys.com)